摘要
目的探讨芪丹息敏颗粒治疗慢性荨麻疹的临床疗效及对外周血T淋巴细胞的影响。方法慢性荨麻疹患者60例,按随机数字表法分为治疗组和对照组,各30例,治疗组口服芪丹息敏颗粒,对照组口服氯雷他定分散片,连续用药2个月,在用药开始后的10 d,20 d,30 d,60 d时对瘙痒程度、风团数目等进行评估,各组在用药前和用药60天时静脉采血,采用流式细胞仪测定外周血T淋巴细胞亚群(CD3+、CD4+、CD8+)的数目和CD4+/CD8+比值,评价其临床疗效。结果治疗组和对照组30天时疗效相当,差异无统计学意义(P>0.05);60天时,治疗组优于对照组,差异具有统计学意义(P<0.05)。治疗组60天时CD3+、CD8+上升(P<0.01),CD4+、CD4+/CD8+下降(P<0.01),而对照组治疗后T淋巴细胞亚群各指标均无明显变化。结论慢性荨麻疹患者体内免疫平衡失调,芪丹息敏颗粒可使紊乱的免疫功能趋于正常,从而减少了该病的复发,提高了疗效。
Objective To investigate the effect of Qidan Ximin particles in treatment of chronic urticaria and peripheral blood T lymphocyte. Methods 60 cases of chronic urticaria patients, randomly divided into treatment group and control group, 30 cases each, the treatment group veleived Qidan Ximin granule orally, while the control group was treated with loratadine dispersible tab- lets, for 2 months, Itching degree, wheal numbers were assessed at 10,20,30 and 60 days since treatmert for determination of pe- ripheral blood T lymphocyte subsets count （ CD3 ＋ , CD4 ＋ , CD8 ＋） the ratio of CD4 ＋ / CD8 ＋. Results The efficacy between two groups were similar at 30 days （ P 〉 0.05 ）. The effect was better in treatment group when compared to control group at 60 days （P 〈 0.05）. CD3 ＋ , CD8 ＋ were increased in treatment group at 60 clays （ P 〈 0.01 ） , CD4 ＋ , CD4＋ / CD8 ＋ ration were de- creased （P 〈 0.01 ）, while there were no significant changes in the control group after treatment. Conclusion Qidan Ximin parti- cles can make the immune function disorder tend to be normal in patients with chronic urticaria, thereby reducing the recurrence of the disease and improving, the efficacy.
出处
《时珍国医国药》
CAS
CSCD
北大核心
2014年第4期880-882,共3页
Lishizhen Medicine and Materia Medica Research
基金
广西中医药大学校级课题(No.P2012083)
关键词
慢性荨麻疹
免疫学
芪丹息敏颗粒
药效学
Chronic urticaria
Immunology
Qidan Ximin particle
Pharmacodynamics
